Literature DB >> 20687826

Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

Agustini Utari1, Weerasak Chonchaiya, Susan M Rivera, Andrea Schneider, Randi J Hagerman, Sultana M H Faradz, Iryna M Ethell, Danh V Nguyen.   

Abstract

Minocycline can rescue the dendritic spine and synaptic structural abnormalities in the fragile X knock-out mouse. This is a review and preliminary survey to document side effects and potential outcome measures for minocycline use in the treatment of individuals with fragile X syndrome. We surveyed 50 patients with fragile X syndrome who received minocycline for at least 2 weeks and found that the most common reported side effect is gastrointestinal difficulty, including loss of appetite. The families reported an improvement in language and behavioral areas. Outcome measures in the design of future randomized clinical trials should include both behavioral and language measures. As with any other treatments, we emphasize that randomized clinical trials are needed to determine the efficacy of minocycline in fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687826      PMCID: PMC4031088          DOI: 10.1352/1944-7558-115.5.433

Source DB:  PubMed          Journal:  Am J Intellect Dev Disabil        ISSN: 1944-7558


  65 in total

1.  No findings of dental defects in children treated with minocycline.

Authors:  Antonio Cascio; Chiara Di Liberto; Matteo D'Angelo; Chiara Iaria; Francesco Scarlata; Lucina Titone; Giuseppina Campisi
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.

Authors:  A J Verkerk; M Pieretti; J S Sutcliffe; Y H Fu; D P Kuhl; A Pizzuti; O Reiner; S Richards; M F Victoria; F P Zhang
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

Review 3.  Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity.

Authors:  Andrés R Sánchez; Roy S Rogers; Phillip J Sheridan
Journal:  Int J Dermatol       Date:  2004-10       Impact factor: 2.736

Review 4.  Minocycline.

Authors:  M Jonas; B A Cunha
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

Review 5.  Minocycline: stain devil?

Authors:  M L Good; D L Hussey
Journal:  Br J Dermatol       Date:  2003-08       Impact factor: 9.302

6.  Why minocycline can cause systemic lupus - a hypothesis and suggestions for therapeutic interventions based on it.

Authors:  M A M van Steensel
Journal:  Med Hypotheses       Date:  2004       Impact factor: 1.538

7.  Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury.

Authors:  David P Stirling; Kourosh Khodarahmi; Jie Liu; Lowell T McPhail; Christopher B McBride; John D Steeves; Matt S Ramer; Wolfram Tetzlaff
Journal:  J Neurosci       Date:  2004-03-03       Impact factor: 6.167

Review 8.  The mGluR theory of fragile X mental retardation.

Authors:  Mark F Bear; Kimberly M Huber; Stephen T Warren
Journal:  Trends Neurosci       Date:  2004-07       Impact factor: 13.837

Review 9.  A fragile balance: FMR1 expression levels.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Hum Mol Genet       Date:  2003-09-02       Impact factor: 6.150

10.  Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat.

Authors:  Sang M Lee; Tae Y Yune; Sun J Kim; Do W Park; Young K Lee; Young C Kim; Young J Oh; George J Markelonis; Tae H Oh
Journal:  J Neurotrauma       Date:  2003-10       Impact factor: 5.269

View more
  46 in total

Review 1.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

Review 2.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 3.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

4.  A 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study.

Authors:  S S Hall; J L Hammond; M Hirt; A L Reiss
Journal:  J Intellect Disabil Res       Date:  2012-04-25

5.  FRAGILE X SYNDROME: PSYCHIATRIC MANIFESTATIONS, ASSESSMENT AND EMERGING THERAPIES.

Authors:  Paula M Wadell; Randi J Hagerman; David R Hessl
Journal:  Curr Psychiatry Rev       Date:  2013-02-01

6.  TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.

Authors:  C Kağan Gürkan; Randi J Hagerman
Journal:  Res Autism Spectr Disord       Date:  2012-10-01

Review 7.  Treatment of neurodevelopmental disorders in adulthood.

Authors:  Eero Castrén; Ype Elgersma; Lamberto Maffei; Randi Hagerman
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

8.  Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.

Authors:  Randi Hagerman; Gry Hoem; Paul Hagerman
Journal:  Mol Autism       Date:  2010-09-21       Impact factor: 7.509

Review 9.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.

Authors:  Claudia Bagni; Flora Tassone; Giovanni Neri; Randi Hagerman
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.